Minimal Residual Disease (MRD) Testing for AML
_

Overview Minimal Residual Disease (MRD) testing is a crucial diagnostic service for patients with Acute Myeloid Leukemia (AML). MRD refers to the small number of leukemia cells that may remain in a patient’s body after treatment, which are undetectable by traditional methods. Identifying MRD is essential for assessing treatment efficacy, monitoring disease progression, and guiding therapeutic decisions to achieve better patient outcomes.

Key Features of Our MRD Testing Service
_
  • High SensitivityDetection limits as low as 1 in 10,000 to 1 in 1,000,000 cells.
  • Fast Turnaround TimeQuick reporting to avoid treatment delays.
  • Comprehensive AnalysisUtilization of flow cytometry, PCR-based assays, or NGS (Next-Generation Sequencing) for accurate MRD detection.
  • Expert SupportOur experienced hematologists and laboratory professionals provide insights into results and recommendations.
Why is MRD Testing Important in T-ALL?
_

Early Detection

MRD testing helps detect residual leukemia cells at extremely low levels, allowing for early intervention before a potential relapse.

Treatment Guidance

Results from MRD testing provide insights into the success of chemotherapy, stem cell transplantation, or targeted therapies.

Personalized Care

By identifying patients with higher MRD levels, clinicians can tailor treatment plans to reduce the risk of recurrence.

Improved Prognosis

Monitoring MRD over time helps predict disease progression, empowering healthcare providers to enhance long-term outcomes.
Our MRD Testing Service
_
Our MRD testing service uses advanced technology like flow cytometry, PCR, and next-generation sequencing (NGS) to detect minimal residual disease with exceptional sensitivity. We provide comprehensive reports with actionable insights, including quantitative MRD levels and clinical interpretations, ensuring accurate and timely results. Our expert team collaborates with healthcare providers to support informed decision-making, while prioritizing patient care through a compassionate and confidential approach.
Benefits of Choosing Us
_
  • Fast Turnaround Time
  • High Sensitivity and Accuracy
  • Detailed and Easy-to-Understand Reports
  • Experienced Laboratory and Clinical Team
Why Choose Us?
_
  • Advanced TechnologyWe utilize cutting-edge techniques like flow cytometry, PCR, and next-generation sequencing (NGS) to achieve highly sensitive and accurate detection of residual leukemia cells.
  • Comprehensive ReportsOur detailed reports include actionable insights, quantitative MRD levels, and expert clinical interpretations to support precise treatment decisions.
  • Fast Turnaround TimesWe prioritize timely delivery of results to ensure prompt and effective decision-making.